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ABSTRACT
Transcriptional co-activator LEDGF/p75 is the major
cellular interactor of HIV-1 integrase (IN), critical
to efficient viral replication. In this work, a series
of INs from the Betaretrovirus, Gammaretrovirus,
Deltaretrovirus, Spumavirus and Lentivirus retro-
viral genera were tested for interaction with the
host factor. None of the non-lentiviral INs posse-
ssed detectable affinity for LEDGF in either pull-
down or yeast two-hybrid assays. In contrast, all
lentiviral INs examined, including those from bovine
immunodeficiency virus (BIV), maedi-visna virus
(MVV) and equine infectious anemia virus (EIAV)
readily interacted with LEDGF. Mutation of Asp-366
to Asn in LEDGF ablated the interaction, sugges-
ting a common mechanism of the host factor
recognition by the INs. LEDGF potently stimulated
strand transfer activity of divergent lentiviral INs
in vitro. Unprecedentedly, in the presence of the
host factor, EIAV IN almost exclusively catalyzed
concerted integration, whereas HIV-1 IN promoted
predominantly half-site integration, and BIV IN was
equally active in both types of strand transfer.
Concerted BIV and EIAV integration resulted in
5 bp duplications of the target DNA sequences.
These results confirm that the interaction with
LEDGF is conserved within and limited to
Lentivirus and strongly argue that the host factor
is intimately involved in the catalysis of lentiviral
DNA integration.
INTRODUCTION
Retroviruses are distinguished by reverse transcription of
their RNA genomes and integration of the resulting
cDNA replicas into a host cell chromosome. Members of
the Retroviridae family can be subdivided into several
genera, of which five were isolated from mammals:
Betaretrovirus, Gammaretrovirus, Deltaretrovirus,
Spumavirus and Lentivirus. The two remaining genera,
Alpharetrovirus and Epsilonretrovirus, are retroviruses from
birds and fish respectively [(1) and http://www.ncbi.nlm.
nih.gov/ICTVdb]. DNA integration is essential for replication
of human lentiviruses HIV-1 and HIV-2 and is fundamental
to the viral persistence that leads to AIDS (2–4) (http://
www.retroconference.org/2006/). Integrase (IN) is the virus-
encoded enzyme responsible for the key catalytic events asso-
ciated with integration [reviewed in (5)]. IN acts on the linear
double stranded cDNA molecule generated by reverse tran-
scription of the retroviral genomic RNA. In a reaction termed
30-processing, IN trims the 30-termini of the cDNA exposing
30 hydroxyls of the invariant CA dinucleotides. A dinu-
cleotide is removed from the U3 and U5 termini of HIV-1
cDNA. Next, IN inserts the processed 30-termini of the viral
cDNA into opposing strands of the chromosomal DNA. Inte-
grated viral cDNA is initially flanked by a pair of short
single-stranded gaps, which are repaired by host cell enzymes
to produce a stable provirus.
Retroviral integration is not entirely random with respect to
the target DNA. Weak consensus integration site sequences
have been reported for HIV-1, avian sarcoma leukosis virus
(ASLV) and murine leukemia virus (MLV) (6). Furthermore,
on the genomic scale retroviruses display distinct, genus-
specific patterns of preferred integration regions [reviewed
in (7)]. The lentiviruses whose integration site preferences
have been reported to-date [HIV-1, HIV-2, simian immuno-
deficiency virus (SIV), equine infectious anemia virus
(EIAV) and feline immunodeficiency virus (FIV)] share a
strong bias toward integration within transcription units
(8–13), whereas a gammaretrovirus MLV favors transcription
start sites and CpG islands (9). Integration of an alpharetro-
virus ASLV and a spumaretrovirus prototype foamy virus
(PFV) appears to correlate only weakly with gene expression
(14–17). These observations collectively suggested a play of
virus- or genus-specific mechanisms for integration target
selection.
Of several cellular proteins implicated in retroviral integra-
tion, transcriptional co-activator p75 received considerable
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attention since its identification as an interactor of HIV-1 IN
(18–20) [for recent reviews see (21,22)]. P75, commonly
referred to as lens epithelium-derived growth factor
(LEDGF), is a nuclear chromatin-associated protein, ubiqui-
tously expressed at all stages of development (23–26).
Early work has implicated LEDGF and its alternative splice
form p52 in regulation of gene expression (23,27,28).
Recently, LEDGF was shown to associate with JPO2, an
interactor of the transcription factor and proto-oncogene
c-Myc, corroborating its role in transcription regulation
(29). LEDGF interacts with HIV-1 IN via the integrase bind-
ing domain (IBD) found within its C-terminal region (resi-
dues 347–429) (24,30). A solution structure of the isolated
IBD and a crystal structure of the IBD in complex with the
catalytic core domain (CCD) of HIV-1 IN have been recently
reported (31,32). The IBD adopts a compact, a-helical fold,
reminiscent of a pair of HEAT repeats (31). The tip of its
finger-like structure binds at the dimer interface of the IN
CCD (32). In addition to the CCD, the aminoterminal domain
of HIV-1 IN required for high-affinity binding is thought to
be involved in the protein–protein interaction (25). LEDGF
dramatically alters biochemical properties of recombinant
HIV-1 IN and potently stimulates its enzymatic activity
(18,24,33,34).
When expressed in human cells, HIV-1 IN stably asso-
ciates with mitotic chromosomes (35,36). This property was
found to be strictly dependent on the endogenous LEDGF,
which appears to tether the viral protein to chromosomal
DNA (20,25,37,38). These findings suggested that through
its interaction with IN, LEDGF could direct HIV-1 preinte-
gration complex (PIC) to its preferred genomic loci. Concor-
dantly, functional HIV-1 PICs could be immunoprecipitated
with antibodies to LEDGF (37). Activity of HIV-1 PICs
partially disrupted by treatment in high ionic strength
conditions could be rescued by recombinant LEDGF (39).
Moreover, a partial knock-down of endogenous LEDGF in
target cells resulted in statistically-significant reduction of
HIV-1 integration into transcription units (40). In addition,
HIV-1 integration could be in part re-targeted in vitro to
the vicinity of a phage lambda repressor binding site by a
chimeric protein containing the IBD fused to the DNA bind-
ing domain of lambda repressor (41). Current reports from
several groups indicate that LEDGF plays a critical role in
HIV-1 DNA integration and is required for efficient viral
replication (42–45) (http://www.ascb.org).
In addition to HIV-1 IN, LEDGF was shown to bind pri-
mate lentiviral HIV-2 and SIV INs, as well as divergent
FIV IN; whereas no interaction was detected between
LEDGF and the INs from a gammaretrovirus MLV, deltare-
trovirus human T cell lymphotropic virus type 2 (HTLV-2)
and alpharetrovirus ASLV (20,34,37). Accordingly, knock-
down of LEDGF expression in target cells did not affect
MLV, while significantly impairing HIV-1 and FIV inte-
gration (45). Although a functional interaction with LEDGF
has only been demonstrated for HIV-1 IN, the available
data seem to indicate it is universal within but limited to
Lentivirus. The present study was designed to test this
conjecture and to clarify whether the modulation of
enzymatic activities by LEDGF is a conserved feature of
lentiviral INs.
MATERIALS AND METHODS
Viral DNA and PCR primers
Molecular clones KV1772 (46), pBIV127 (47), pSPeiav19
(48), pEECC-FeLV (49), pcHSRV2 (50) were sources of
maedi-visna virus (MVV), bovine immunodeficiency virus
(BIV), EIAV, feline leukemia virus (FeLV) and PFV DNA,
respectively. Genomic DNA of Akata cells infected with
Mason-Pfizer monkey virus (MPMV) served as template for
amplification of the MPMV IN coding sequence (CDS).
HTLV-1 DNA was from a clinical isolate.
The following oligodeoxynucleotides were synthesized by
Invitrogen: PC122, GCGCGTCGACTTCTTTTTGTATTTC-
TTTTGGTGG; PC123, TGTGGATAGAAAATATTCCC;
PC124, GCGCGTCGACATTTGGTTTTATTAGTAACTT-
AGTCC; PC125, TGTGGGTAGAAAATATTCAGG;
PC126, GCGCGTCGACCGAACTCCCATCTTGGATATC;
PC127, TGTTCCTAGAAAATATCCCCTC; PC138, CCCC-
ACAGTACTGTTGGGTGTTCTTCACC; PC139, GGCGG-
GTACCTTCAGCTCGTGTAGCTCA; PC140, CACCCAA-
CAGTACTGTGGGGCAGGGTGG; PC141, GGCGGAATT-
CGTACAGAGTGAAGATATGG; PC142, TCAGGGACCC-
GGGTTCCTAGAAAATATCCCCT; PC143, GCCTTGAA-
GTCCTCTTTCAGGGACCCGGGTTCC; PC144, GGCCC-
TCGAGTCACGAACTCCCATCTTGG; PC145, GCGCGT-
CGACTTCATTTTTTTCCAAATGATCCATTG; PC146,
TGAAAGGATATCCCAAACAATATAC; PC155, TGTTC-
CTGGAAAAAATAGAGCC; PC156, GCGCGTCGACTGC-
CATTTCTCCATCCTC; PC160, GCGCGTCGACATTGAA-
CAAGATGGATTGCACG; PC161, TGAGTAACATAAAC-
ACAAACCTCG; PC169, GGCGGGTACCGGCACTCAGA-
TTCTGCGGTC; PC170, GGCGGAATTCCAATTGTCAG-
AATACAAGCAC; PC171, CCCACAGTACTGTAGGATC-
TCGAACAG; PC172, GATCCTACAGTACTGTGGGGTT-
TTTATGAGG; PC173, GAGCCCCGGGTGGGTAGAAAA-
TATTCAGG; PC174, GCGCGGATCCTCAATTTGGTTTT-
ATTAGTAACTTAG; PC175, TGCAGCTCTCTCCTGCA-
GACC; PC176, GCGCGTCGACCCCATGGTGTTGGTGG-
TCTTTTTCTTTGG; PC186, GCGCGTCGACAGTTCCAC-
GAGAGAGTC; PC187x, TGCCCACTGAACTTATAGA-
GG; PC188, TACCTGGTACCTGTACTGGGTCTCTCTGG;
PC192, GGCGGGTACCAGAAAGCAGGTAGCTTGCAG-
TGG; PC193, GGCGGGTACCCGAAGAACTCCAGCATG-
AGATCC; PC200, CGCACCTCCTCCCTGGGCTTCGG-
AC; PC203, TTTTCCTTATTTTCTGAGTAAGG; PC204,
GAAAGGACAACATGAGAAAGAGGC; PC206, CTATC-
AATTACACATTAACATACACAC; PC210, GGACTGAG-
GGGCCTGAAATGAGC; PC214, CCATTACAAACTTCT-
CAAATGTTCTTTATATTCCAGG; PC217, GTAAGCCC-
ACTGCAAGCTACC; PC218, GGATCTCATGCTGGAGT-
TCTTCG; T3P, GCAATTAACCCTCACTAAAGG.
DNA constructs for protein expression
To make constructs for production of C-terminally
His6-tagged INs, DNA fragments encoding HIV-2, MVV,
BIV, EIAV, MPMV, FeLV, HTLV-1 and PFV INs were
PCR-amplified using Pfu DNA polymerase (Stratagene) and
the primer pairs PC155/PC156, PC123/PC122, PC127/
PC126, PC125/PC124, PC161/PC160, PC187x/PC186,
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PC175/PC176 and PC146/PC145, respectively. Resulting
amplicons digested with SalI were ligated between NdeI
and SalI sites of pET20-b(+) (Novagen) (NdeI site of the vec-
tor was filled-in using Pfu polymerase to allow blunt-end
ligation). The plasmid pKB-IN6H used for bacterial expres-
sion of HIV-1 IN with a C-terminal His6-tag has been
described (25).
To make pCPH6P-BIV-IN, for production of BIV IN with
N-terminal His6-tag and a human rhinovirus (HRV) 3C pro-
tease cleavage site, a PCR fragment obtained using primers
PC143 and PC144 and re-amplified using primers PC142
and PC144, was digested with XhoI and ligated between
NdeI and XhoI sites of pET15b (Novagen) (NdeI site of the
vector was filled-in to allow blunt-end ligation). To make
pCPH6P-EIAV-IN for expression of EIAV IN with a remov-
able His6-tag, a PCR amplicon obtained with primers PC173
and PC174 was digested with XmaI and BamHI and sub-
cloned into pCPH6P-BIV-IN, to replace the BIV IN CDS.
The plasmids pRP1012, pCP-Nat75 and pCP-Nat75(D366N)
were used for bacterial expression of HIV-1 IN with an
N-terminal His6-tag and a thrombin cleavage site, non-tagged
human LEDGF and LEDGF(D366N), respectively
(25,31,51).
DNA substrates for integration assays
To make pBIV-U3U5, RU5 and U3 fragments of the BIV
long terminal repeat (LTR) were PCR-amplified using pri-
mers pairs PC138/PC139 and PC140/PC141 respectively
and spliced by re-amplification with primers PC139 and
PC141. The resulting amplicon digested with KpnI and
EcoRI was ligated between KpnI and EcoRI sites of
pBK-RSV (Stratagene). To make pEIAV-U3U5, RU5 and
U3 fragments of the EIAV LTR PCR-amplified using primer
pairs PC169/PC171 and PC170/PC172 were spliced in a PCR
with primers PC169 and PC170. The resulting amplicon was
digested with KpnI and EcoRI and subcloned into pBK-RSV.
Mini-viral substrates for HIV-1, BIV and EIAV INs were
prepared by digestion of pU3U5 (51), pBIV-U3U5 and
pEIAV-U3U5 with ScaI, respectively.
To obtain RU5 substrates for HIV-1, BIV and EIAV INs,
PCR fragments obtained using Taq DNA polymerase and
T3P primer in combination with PC188, PC139, and
PC169, respectively, and pU3U5, pBIV-U3U5 and pEIAV-
U3U5 as templates, respectively, were digested with ScaI
and the RU5-containing fragments were purified by elec-
trophoresis through 2% agarose gels. The longer RU5+300
donors were obtained in a similar fashion, substituting
PC188, PC139 or PC169 for PC210 primer that anneals
300 bp upstream of the KpnI site of the mini-viral constructs.
Where indicated, the reactive strands of the RU5 substrates
were 50 end labeled using T4 polynucleotide kinase (New
England Biolabs) and [g-32P]ATP (GE Healthcare).
Recombinant proteins
Endonuclease A-deficient Escherichia coli strain PC2
[BL21(DE3), endA::TetR, T1R, pLysS], recovered as a spon-
taneous T1 phage-resistant mutant of PC1 (51,52), was used
for protein production. Shake flask cultures of PC2 trans-
formed with various expression constructs were grown in
LB medium at 30C to an A600 of 0.9–1.0 prior to induction
with 0.25 mM isopropyl-thio-b-D-galactopyranoside. Follow-
ing 4 h induction at 25–28C, bacteria were harvested and
stored at 70C.
To isolate His6-tagged retroviral IN proteins, thawed bacte-
rial paste was sonicated in buffer B (1 M NaCl, 7.5 mM
CHAPS, 50 mM Tris–HCl, pH 7.4) containing 0.5 mM
phenylmethlysulfonyl fluoride and 15 mM imidazole. Crude
extracts pre-cleared by centrifugation were incubated with
Ni NTA agarose (Qiagen). The resin was extensively washed
in buffer B containing 15 mM imidazole, and His6-tagged
proteins were eluted with 200 mM imidazole in buffer B.
IN-containing fractions diluted with 3 volumes of 50 mM
Tris–HCl, pH 7.4 were injected into a 5 ml HiTrap Heparin
column (GE Healthcare), and bound proteins were eluted
with a linear gradient of 0.25–1 M NaCl in 50 mM Tris–
HCl, pH 7.4. Immediately after elution, 10 mM DTT was
added to each fraction and NaCl concentration was adjusted
to 1 M. HIV-1, BIV and EIAV INs produced to carry cleav-
able N-terminal His6-tags were digested with thrombin
(3 NIH units of thrombin per mg of His6-tagged IN) for
3 h at 25C in the presence of 20 mM b-mercaptoethanol
or HRV14 3C protease (20 mg of protease per mg of His6-
tagged IN) for 6–12 h at 4C in the presence of 20 mM
DTT; the tag-free INs were then purified by chromatography
on Heparin sepharose as above.
Wild type and D366N LEDGF were made as previously
described (24,25,31). Purified proteins supplemented with
10% glycerol were flash-frozen in liquid nitrogen and stored
at 70C. Protein concentration was determined using
Bradford assay (Bio-Rad Laboratories) with a BSA standard.
Where indicated, molar concentrations refer to monomer
protein forms.
His6-tag pull-down assays
His6-tag pull-down assays were done as previously described
(25,31). Briefly, 4 mg wild type or D366N LEDGF was incu-
bated with 6.7 mg C-terminally His6-tagged retroviral IN,
10 mg BSA and 15 ml Ni-NTA agarose (settled bead volume)
in 650 ml pull-down buffer [PB, 150 mM NaCl, 2 mM MgCl2,
25 mM imidazole, 0.1% Nonidet P40 and 50 mM Tris–HCl
(pH 7.4)] for 4–5 h at 4C with gentle rocking. The beads
washed trice in ice-cold PB were boiled in 16 ml 2· Laemmli
Laemmli sample buffer containing 50 mM ethylene-
diaminetetraacetic acid (EDTA) and 50 mM DTT. Eluted
proteins were separated by electrophoresis by SDS–PAGE
and detected by staining with Coomassie-R250.
Sequence analysis of equine and bovine LEDGF cDNAs
Two partial cDNA sequences (GenBank accession nos.
CX598499 and CD528249) spanning 900 bp of the equine
LEDGF CDS were identified using translated BLAST.
PC204, PC200 and PC206 primers were designed based on
this known sequence and conserved portions of 50- and
30-untranslated regions (30-UTRs) of mammalian LEDGF
cDNA sequences. Total RNA extracted from Equus
caballus-derived cell line NBL-6 was reverse-transcribed
using random-primed Superscript III (Invitrogen). Sequen-
cing of a 1 kb PCR fragment obtained using Easy-A DNA
polymerase (Stratagene) primed by PC204 and PC206
revealed 300 bp of the 30-UTR sequence of the equine
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cDNA. Finally, a 1.6 kb PCR fragment obtained using
Easy-A with PC200 and PC214 revealed complete and
unbiased CDS of the equine LEDGF cDNA. The sequences
determined in this work were submitted to GenBank (acces-
sion codes DQ829781 and DQ873682). The entire CDS of
the bovine LEDGF cDNA could be reconstructed from the
available partial sequences (GenBank accession codes
AF474175, CR382879, DN537967, DN536615, DT857195,
DN533664, DT885845, DV915861, DT896093, DN535088,
DV916069, DV913569 and DV827864).
In vitro integration assays
Tag-free preparations of HIV-1, BIV or EIAV INs were used
in all enzymatic assays. Reaction conditions were essentially
as previously described for the HIV-1 enzyme (18,24,31).
Briefly, 2 ml IN [in dilution buffer (DB), 750 mM NaCl,
10 mM DTT and 10 mM Tris–HCl (pH 7.8)] or 2 ml DB
was added to 36 ml master mixture containing appropriate
substrate and target DNA in 42 mM NaCl, 6 mM MgSO4,
4.8 mM ZnCl2, 12.1 mM DTT, and 24.2 mM HEPES,
pH 7.4. Samples were incubated at 25C for 5–7 min before
addition of 2 ml LEDGF (0–0.54 mg/ml in DB) and then at
37C for 90 min. Mini-HIV, -BIV, and -EIAV donor DNA
substrates were used at 2.5 nM (300 ng per 40 ml reaction),
RU5 and RU5+300 were used at 10 nM. Supercoiled pGEM-
9Zf() (300 ng) served as target DNA in the assays with RU5
and RU5+300 donors.
Integration reactions were stopped by addition of 0.5%
SDS and 25 mM EDTA and deproteinized by digestion
with 30 mg proteinase K (Roche Applied Science) for
45–60 min at 37C followed by ethanol precipitation. DNA
products separated in 0.8 or 1.5% agarose gels in
Tris–acetate–EDTA buffer were visualized by staining with
ethidium bromide. Singly-nicked pGEM-9Zf() DNA, used
as migration standard for agarose gel electrophoresis, was
prepared by digestion of the supercoiled plasmid with
DNase I (Roche Applied Science) in the presence of satura-
ting amounts of ethidium bromide (53). Radioactively-
labeled reaction products were detected and quantified by
phosphor autoradiography using a Storm-860 scanner (GE
Healthcare).
Sequence analysis of BIV and EIAV integration
products
Strand transfer products from upscaled reactions of BIV or
EIAV INs with the respective RU5 donors and supercoiled
pGEM-9Zf() target DNA were separated by electrophoresis
in 1.5% agarose gels. The linear concerted integration
products isolated from the gels were treated with phi29
DNA polymerase (New England Biolabs) in the presence of
200 mM of each deoxynucleotide triphosphate, digested with
KpnI, and ligated with KpnI-digested kanamycin-resistance
cassette. The cassette, containing the Tn5 aminoglycoside-
30-O-phosphotransferase gene, was obtained in a PCR using
Easy-A DNA polymerase, PC192 and PC193 primers, and
pCP15 (52) template. E.coli XL1-Blue cells transformed
with the ligation products were selected with 35 mg/ml kana-
mycin. Plasmids isolated from individual colonies were
sequenced using primers PC217 and PC218 annealing to
the flanking regions of the kanamycin-resistance cassette.
RESULTS
Interaction with LEDGF is limited to and conserved
among lentiviral INs
A series of IN proteins of lentiviral and non-lentiviral origins
produced with identical C-terminal His6-tags were tested for
interaction with recombinant human LEDGF in a pull-down
assay using Ni-NTA agarose beads (25,31). In agreement
with published observations (20,25,31,34), HIV-1 and
HIV-2 INs readily bound LEDGF (Figure 1A, lanes 2 and
4). LEDGF was not recovered when IN was omitted
(Figure 1B, lane 2), and the Q168A substitution close to
the HIV-1 IN binding interface (20,32) precluded the
interaction (Figure 1A, lane 3). Under identical conditions
betaretroviral MPMV, gammaretroviral FeLV, deltaretroviral
HTLV-1 and spumaretroviral PFV INs failed to pull-down
LEDGF (Figure 1A, lanes 5–8). In contrast, lentiviral
EIAV, MVV and BIV INs reproducibly retained LEDGF
on the Ni-NTA beads (Figure 1B, lanes 5–7). LEDGF residue
Asp366 plays a crucial role in recognition of HIV-1 IN, form-
ing a bidentate hydrogen bond with main chain amides of IN
Figure 1. Interaction with LEDGF is limited to and conserved among
lentiviral INs. (A) His6-tagged HIV-1, HIV-2, PFV, MPMV, FeLV and
HTLV-1 INs (as indicated) were tested for the ability to pull-down WT (lanes
2–8) or D366N LEDGF (lanes 10 and 11). Proteins recovered on Ni-NTA
agarose beads were separated in SDS–PAGE gels and detected by staining
with Coomassie-R250. Lanes 1 and 9 contained input quantities of WT and
D366N LEDGF, respectively. The migration positions of LEDGF and
molecular weight markers (kDa) are indicated. (B) His6-tag pull-down assays
with lentiviral HIV-1, EIAV, MVV and BIV INs (as indicated) and WT
(lanes 3–7) or D366N LEDGF (lanes 10–14). Lanes 1 and 8 contained input
quantities of WT and D366N LEDGF. IN was omitted from reactions in
lanes 2 and 9.
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residues Glu-170 and His-171 (32), and LEDGF mutants
D366A and D366N are deficient for interaction with HIV-1
IN (31). Similar to HIV-1 IN (Figure 1A and B, lanes 10),
none of the lentiviral INs studied here pulled down the
LEDGF D366N mutant (Figure 1A, lane 11; Figure 1B,
lanes 12–14), suggesting that divergent lentiviral INs share
the structural basis for the host factor recognition.
Recent results indicate that applied to the IN-LEDGF inter-
action, yeast two-hybrid assays can be more sensitive than
in vitro pull-down experiments. Residual interactions
between LEDGF and several point mutants of HIV-1 IN
(e.g. Q168A, V165A and R166A) could be revealed by
yeast two-hybrid analyses, while evading detection by
His6-tag pull-down (20,31,54). In agreement with the results
of the pull-down assays described here, no interaction
between LEDGF326–471 and non-lentiviral INs (MPMV,
FeLV, HTLV-1 and PFV) could be detected in a GAL4-
based yeast two-hybrid assay, under conditions that readily
revealed binding of the co-factor to HIV-1 and FIV INs
(Supplementary Figure S1). Furthermore, the D366N muta-
tion in LEDGF disrupted the interactions with both HIV-1
and FIV INs (Supplementary Figure S1), corroborating a
common structural mechanism of host factor recognition by
divergent lentiviral INs.
Sequence analysis of bovine and equine LEDGF cDNAs
An issue in this study was the use of human LEDGF in vari-
ous assays with INs from non-primate retroviruses. LEDGF is
known to be well conserved in mammals (24). For instance,
the human and feline orthologs share 96.4% identical and
97.9% similar residues (30). To justify using human
LEDGF in enzymatic assays involving BIV and EIAV INs,
sequences of bovine and equine LEDGF cDNAs were ana-
lyzed. A DNA fragment spanning the entire CDS of the
E.caballus LEDGF cDNA could be amplified by RT–PCR
from RNA of horse NBL-6 cells, whereas the complete
CDS of the Bovis taurus LEDGF cDNA could be recon-
structed from available partial sequences. Alignments of the
predicted protein sequences revealed only minor differences
between the human, bovine and equine LEDGF orthologs
(Supplementary Figure S2). Thus, bovine and equine
LEDGF orthologs share 97% identical and 99% similar
residues with the human protein. Of importance, all func-
tional and structural elements so far identified in LEDGF
(i.e. the PWWP domain, the IBD, the NLS and the core
A/T-hook motifs) are identical in the human, mouse, feline,
equine and bovine orthologs.
LEDGF augments enzymatic activity of divergent
lentiviral INs
LEDGF enhances the strand transfer activity of HIV-1 IN as
much as 150-fold under certain in vitro conditions
(18,24,31,33). Notably, the LEDGF-dependent reactions
take place in the absence of organic solvents or molecular
crowding agents, otherwise required to observe efficient
magnesium-dependent activity of HIV-1 IN in vitro (51,55–
59). To establish whether divergent lentiviral INs respond
to LEDGF in a similar way, strand transfer activities of
recombinant HIV-1, BIV and EIAV INs on their respective
mini-viral substrates were studied side-by-side. Mini-HIV
(51), mini-BIV and mini-EAIV substrates, 4.5 kb linear
blunt-ended DNA molecules flanked by U3 and RU5 frag-
ments of the viral LTRs, were designed to mimic the viral
cDNA. In the simplest form of the assay, mini-viral DNA
serves as donor and target DNA and strand transfer products
can be detected by staining with ethidium bromide following
electrophoresis in agarose gels (18,51). Under close-to-
physiological solution conditions [115 mM NaCl, 5 mM
MgCl2, 10 mM DTT and 20 mM Hepes (pH 7.5)] HIV-1,
BIV and EIAV INs were almost inactive in the absence of
LEDGF, yielding barely detectable levels of strand transfer
products (Figure 2, lanes 2, 7, 12). In agreement with previ-
ous observations (18), addition of LEDGF unleashed the
strand transfer activity of HIV-1 IN (Figure 2, lanes 3–5).
More than 50% of input mini-HIV DNA was converted
into various products, including those that failed to enter
the 0.8% agarose gel, in the presence of 0.4 mM LEDGF
(Figure 2, lane 5). Similarly, LEDGF stimulated strand trans-
fer activities of BIV and EIAV INs on their respective mini-
viral DNA substrates (Figure 2, lanes 8–10, 13–15). Of note,
the range of reaction products was IN-specific, each enzyme
generating a reproducible and unique pattern.
Fidelity of LEDGF-dependent strand transfer in vitro
varies among INs
Although INs mediate concerted integration of both ends of
the retroviral cDNA in vivo, their pure recombinant forms
are prone to uncoupled single-LTR (termed half-site) strand
transfer. IN assays utilizing long mini-viral DNA substrates
proved useful to visualize gross strand transfer activity
(18,51). However, the complexity of the reaction products
hampers their finer analyses. The use of shorter donor sub-
strates in the presence of excess supercoiled target DNA
greatly reduce complexity of the reaction products, the
major being circular half-site, resulting from integration of
a single-LTR into one strand of the target plasmid, and/or lin-
ear concerted, from integration of pairs of LTRs into oppos-
ing strands of the target DNA (Figure 3A) (56,60). To
compare fidelity of LEDGF-dependent strand transfer by
HIV-1, BIV and EIAV INs (herein, fidelity refers to relative
efficiency of concerted versus half-site strand transfer), the
enzymes were incubated with blunt-ended donor DNA
molecules containing respective viral RU5 sequences in the
Figure 2. LEDGF stimulates gross strand transfer activity of HIV-1, BIV
and EIAV INs. Reactions containing mini-HIV (lanes 1–5), mini-BIV
(lanes 6–10) or mini-EIAV (lanes 11–15) DNAs were incubated in the
presence of 0.6 mM (20 mg/ml) non-tagged recombinant HIV-1 (lanes 2–5),
BIV (lanes 7–10) or EIAV (lanes 12–15) IN. LEDGF was added to the
reactions in lanes 3–5, 8–10 and 13–15 at indicated concentrations. The
proteins were omitted from the mock reactions in lanes 1, 6 and 11.
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presence of supercoiled plasmid DNA (pGEM), and the reac-
tion products were separated in 1.5% agarose gels. Although
the reaction products were clearly IN-specific, LEDGF stimu-
lated strand transfer activities of all three enzymes, in a
concentration-dependent manner (Figure 3B). In the presence
of the host factor, HIV-1 IN produced a distinct ladder of
products that migrated above the nicked form of the target
DNA (Figure 3B, compare lanes 1, 6 and 17), as expected
for products of single and multiple half-site integration
events.
Reactions containing EIAV IN and the 120 bp EIAV RU5
substrate revealed a major product band migrating as a
3200 bp linear DNA fragment (Figure 3B, lanes 13–16).
The difference in electrophoretic mobility between this
product and linearized pGEM (lane 18) was consistent with
concerted integration of a pair of EIAV RU5 substrate
molecules into the 2912 bp target (see Figure 3A). When
EIAV IN was incubated with a 300 bp longer substrate
(RU5+300, Figure 3C) the resulting product migrated as a
3800 bp DNA fragment, consistent with concerted integra-
tion of a pair of 420 bp substrate molecules into pGEM
(Figure 3C, lane 10). Furthermore, a reaction containing
both RU5 and RU5+300 EIAV substrates resulted in a triplet
of bands, of which two migrated as products of reactions
containing only RU5 or RU5+300 plus one at an intermediate
position (Figure 3C, lane 11). Such a mixed pattern is
Figure 3. Strand transfer activities of HIV-1, BIV and EIAV INs in the presence of LEDGF. (A) Schematic of in vitro integration with circular DNA target and
the expected linear concerted and circular half site strand transfer products. Coordinated insertion of a pair of substrate DNA molecules into opposing strands of
target DNA results in a linear concerted integration product (left). Uncoupled insertion of a single substrate molecule into one strand of the target plasmid gives a
circular half site product (right). Thick lines are substrate and thin are target-derived DNA. (B) HIV-1 (lanes 1–6), BIV (lanes 7–11), or EIAV (lanes 12–16) RU5
substrates and supercoiled pGEM target DNA were incubated with 0.6 mM (20 mg/ml) recombinant HIV-1, BIV, or EIAV INs and 0–0.4 mM LEDGF, as
indicated. Deproteinized reaction products were separated in 1.5% agarose gels and detected by staining with ethidium bromide. Lanes 17 and 18 contained
nicked circular and linearized pGEM DNA respectively. Migration positions of DNA markers (kb), pGEM DNA forms [supercoiled multimer (s.c. mult.), nicked
circular, linear, and supercoiled (s.c.)], substrate RU5 DNAs, and the reaction products (concerted, half-site, and multiple half-site) are indicated. (C) BIV (lanes
1–6) and EIAV (lanes 7–12) integration reactions were carried out with the respective RU5 or/and RU5+300 substrates. Lanes 13 and 14 contained nicked circular
and linearized pGEM DNA, respectively. Migration positions of the two circular half site and three linear concerted integration products derived from RU5 and
RU5+300 substrates are indicated.
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expected only when two substrate molecules are used simul-
taneously in a strand transfer reaction; half-site integration
would result in only two different product bands. Of note,
degradation of target DNA was not observed when donor
DNA substrates were omitted, ruling out contamination of
the protein preparations by a nuclease activity (Figure 3C,
compare lanes 7 and 12). In addition, digests of the material
from the 3800 bp band with KpnI or StuI, which restrict
within the RU5+300 sequence, further confirmed that it con-
sists of linear DNA species flanked by pairs of donor sub-
strate molecules (data not shown). In sharp contrast to its
HIV-1 counterpart, EIAV IN produced only a minor fraction
of circular half-site products, which were barely detectable
following staining with ethidium bromide (Figure 3B, lanes
13–16; Figure 3C, lanes 8–11).
Under similar conditions, BIV IN was proficient in both
concerted and half-site integration (Figure 3B, lanes 7–11;
Figure 3C, lanes 1–6). The products migrating as a distinct
band at 3400 bp (Figure 3B, lanes 10 and 11; Figure 3C,
lane 3) resulted from concerted integration of pairs of 217
bp BIV RU5 molecules into pGEM. The identity of this
band was confirmed by an 4000 bp product obtained in a
reaction with a 517 bp BIV RU5+300 substrate (Figure 3C,
lane 4) and by the characteristic triplet at 3400/3700/
4000 bp revealed when both RU5 and RU5+300 BIV sub-
strates were used in one reaction (Figure 3C, lane 5). In
addition, digests of the 3.7 kb product with KpnI or XhoI,
which restrict within RU5+300 DNA, confirmed its identity
(data not shown). The circular half-site products obtained in
reactions with BIV RU5 substrate migrated above the nicked
form of pGEM (Figure 3B, lanes 10 and 11; Figure 3C,
lane 3). A slower migrating band of circular half-site products
was obtained with the longer RU5+300 BIV substrate
(Figure 3C, lane 4). A reaction containing both BIV RU5
and RU5+300 substrates revealed a pair of bands migrating
at the positions identical to those from reactions containing
either RU5 or RU5+300 (Figure 3C, lane 5), consistent with
a single-LTR strand transfer.
Further differences between activities of the lentiviral INs
were apparent. Thus, HIV-1 and BIV INs effected substantial
nicking of pGEM DNA in LEDGF- and donor DNA-
independent manners (Figure 3B, compare lanes 3, 8 and
13; Figure 3C, lanes 6 and 12). HIV-1 IN is known to possess
a low level of magnesium-dependent endonuclease activity
(55). Also, since EIAV IN prepared in a similar way did
not relax supercoiled pGEM (Figure 3B, lane 13;
Figure 3C, lane 12), endonuclease activity observed in
HIV-1 and BIV IN preparations was unlikely due to a con-
taminant but an intrinsic activity of these enzymes. A high-
molecular weight band reproducibly observed in reaction
with BIV IN when substrate DNA was omitted (Figure 3C,
lane 6 and data not shown) suggested that BIV IN can utilize
randomly nicked DNA to initiate strand transfer, though this
product was not studied in detail. Multiple integration events
(both half-site and concerted) presumably explain additional
product bands and smears observed on the ethidium bromide-
stained gels (Figure 3B and C).
To selectively detect and quantify strand-transfer products,
integration reactions were set-up with radiolabeled RU5 sub-
strates (Figure 4). During the linear phase of the reaction,
LEDGF stimulated half-site activity of HIV-1 IN 19.6
(±0.3) -fold. A light band migrating at 3.5 kb, apparently
the product of concerted integration, was observed in the
reactions (Figure 4, lanes 4–6, also visible in Figure 3B,
lane 6). Since this activity could not be detected in the
absence of the host factor, stimulation of HIV-1 concerted
integration by LEDGF could not be reliably estimated. In
contrast to HIV-1 IN, half-site activity of EIAV IN was not
changed in the presence of LEDGF, while the concerted
integration activity increased at least 60-fold (Figure 4,
lanes 19–27). Both half-site and concerted integration activi-
ties of BIV IN were equally stimulated by the host factor
(Figure 4, lanes 10–18). Although the circular half-site and
concerted products of the LEDGF-dependent BIV reaction
reached a maximum level at 15 min (Figure 4, lane 12),
the reaction products forming secondary product bands and
smears appeared to accumulate at the expense of the residual
free substrate (Figure 4, lanes 13–15).
Sequencing of the BIV and EIAV concerted integration
products
The provirus is flanked by a short duplication of chromo-
somal target DNA sequence (ranging from 4 to 6 bp for
different retroviruses), which results from repair of short
single-stranded gaps created upon integration of the retroviral
cDNA termini into opposing strands (and across the major
groove) of chromosomal DNA. Hence, correct duplication
of target DNA sequences is a hallmark of legitimate retroviral
integration. Specifically, HIV-1 and EIAV proviruses are
flanked by 5 bp duplications of target DNA sequences
(13,61). The 5 bp duplication can be conceivably expected
for other members of Lentivirus. To further characterize
the reaction products and verify target site duplications,
products of concerted integration of BIV and EIAV RU5
substrates into the pGEM target isolated from agarose gels
were treated with strand-displacing phi29 DNA polymerase,
prior to ligation with a kanamycin-resistance cassette
and transformation into E.coli cells. Plasmids isolated
from randomly-picked kanamycin-resistant colonies were
sequenced using primers annealing to the flanks of the cas-
sette. Thirty clones derived from the 3.2 kb EIAV and 26
from the 3.4 kb BIV concerted linear integration products
were analyzed. In all sequenced integration products, the
reactive termini of BIV and EIAV RU5 substrate molecules
underwent correct 30-processing prior to strand transfer.
Twenty-six (86.7%) EIAV and seventeen (65.4%) BIV
product-derived plasmids had the expected structure,
containing pairs of RU5 fragments inserted with 5 bp dupli-
cations of the target sequences; two (7.7%) BIV clones had
6 bp duplications (Figure 5A). Curiously, one EIAV- and
five BIV- derived clones contained solo RU5 fragments
while the second donor fragment was replaced by an A/T
base pair, ligated to the cassette. Because these clones had
5 bp duplications of the target sequences, they were most
likely derived from legitimate concerted integration. Nicking
50 of the reactive deoxyadenosine within one of the integrated
substrate molecules prior to the treatment with phi29 DNA
polymerase could explain their occurrence. The remaining
clones had deletions or rearrangements, possibly due to
the cloning or selection procedures (Figure 5A). In total,
90% (27/30) of EIAV and 92% (24/26) of BIV integration
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product clones appeared to arise from legitimate concerted
integration.
Distribution of the cloned EIAV and BIV integration prod-
ucts along the target DNA did not appear entirely random;
both hot and cold regions were observed (Figure 5B). Inte-
gration events into or close to the replication origin of
pGEM were most likely lost due to the cloning procedure.
The second avoided region, within the bla gene, was less
obvious, as ampicillin was not used to select the integration
product libraries. Overexpression of N-terminal fragments
of b-lactamase can be toxic to E.coli cells (unpublished
observations). Therefore, disruption of bla on a high-copy
plasmid could lead to selective disadvantage. Alignments of
local target sequences from cloned concerted inte-
gration products revealed a weak consensus for EIAV IN
target sequence GTWACNNW (International Union of
Biochemistry codes) (Supplementary Figure S3), which is
remarkably similar to that elaborated for large datasets of
HIV-1 and EIAV integration sites in vivo (6,13). BIV IN dis-
played less bias towards target DNA sequence. Both EIAV
and BIV INs seemed to disfavor integration immediately
next to a deoxythimidine; a similar observation can be
made for lentiviral integration in vivo (6,13).
DISCUSSION
Earlier reports suggested that the interaction with LEDGF is a
conserved and unique feature of lentiviral INs (18–20,34,37).
However, Betaretrovirus and Spumavirus INs were not
included in the previous studies. In addition, HIV-1 IN
remained a single lentiviral IN whose enzymatic activity
was examined in the presence of the co-factor (18,24,33).
Figure 4. Time course of LEDGF-dependent HIV-1, BIV and EIAV integration reactions with radiolabeled donor DNA substrates. HIV-1 (lanes 1–9), BIV
(lanes 10–18) and EIAV (lanes 19–27) RU5 substrates were incubated with their respective INs (0.6 mM) for 5–90 min (as indicated), in the presence (lanes 2–6,
11–15 and 20–24) or absence (lanes 7–9, 16–18 and 25–27) of 0.4 mM LEDGF. Deproteinized reaction products separated in 1.5% agarose gels were detected
and quantified by phosphor autoradiography. Lanes 1, 10 and 19 contained mock samples where IN and LEDGF were omitted. Migration positions of DNA
standards (kb) are indicated. The plot below each gel shows accumulation of the concerted (filled circles) or half-site (triangles) integration products in the
presence (discontinuous line) or absence (dashed line) of LEDGF in terms of relative band intensity. Error bars represent SDs calculated from duplicate
measurements.
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The present work was designed to complement and extend
the prior observations, and included novel INs from
Betaretrovirus (MPMV), Gammaretrovirus (FeLV),
Deltaretrovirus (HTLV-1) and Spumavirus (PFV) alongside
with several Lentivirus INs. The complementary approaches
of in vitro His6-tag pull-down and yeast two-hybrid assays
failed to detect interaction between LEDGF and any of the
non-lentiviral INs from the current study. In contrast, every
lentiviral IN tested here displayed affinity for the host
factor, including novel EIAV, BIV and MVV INs, as well
as previously studied HIV-1, HIV-2 and FIV INs (Figure 1
and Supplementary Figure S1) (18–20,34,37). These results
fully confirm that the interaction with LEDGF is limited to
and conserved within Lentivirus.
In the crystal structure of the HIV-1 IN CCD–IBD
complex, the side chain of LEDGF residue Asp-366 is
involved in a bidentate hydrogen bond with the main chain
amides of Glu-170 and His-171 of IN (32). These contacts
are essential, since D366A and D366N mutations in
LEDGF ablated the interaction with HIV-1 IN (31). In agree-
ment with previous observations (31,54), D366N LEDGF
mutant failed to interact with HIV-1 IN in both pull-down
and yeast two-hybrid assays. Moreover, the point mutation
also ablated the interaction with all other lentiviral INs
studied here (Figure 1A and B, Supplementary Figure S1),
strongly arguing that the divergent INs share the mechanism
of the host factor recognition. Intriguingly, while LEDGF
proteins from the relevant host species are highly conserved
[Supplementary Figure S2, see also (24,30)], lentiviral
INs display significant sequence variations. Thus, INs
from non-primate lentiviruses share only 29–37% identical
residues with the HIV-1 protein; MVV IN included in this
study appears to be most divergent. As revealed by the crystal
structure of the HIV-1 IN CCD–IBD complex, the host factor
forms several key contacts with main chain atoms of IN,
and the interaction is highly sensitive to the polypeptide
backbone conformation at the IN CCD dimer interface (32).
Conceivably, structural conservation of lentiviral INs served
to maintain the interaction within the genus. Yet, it appears
that each lentivirus has evolved a distinct network of addi-
tional contacts. Strikingly, the majority of the HIV-1 IN
residues that contribute side chains to the interaction are
not conserved among lentiviral INs (Figure 6). The most
notable differences affect positions corresponding to the
HIV-1 residues Ala-128, Ala-129, Trp-131, Trp-132 and
Gln-168 (Figure 6). Methyl groups of HIV-1 IN Ala-128
and Ala-129 participate in a hydrophobic pocket that buries
the side chain of the LEDGF hotspot residue Ile-365
(31,32). Substitution of Ala-128 or Ala-129 for a bulkier
Gln residue significantly affected apparent affinity for
LEDGF (54). Nevertheless, lentiviral INs are able to accom-
modate residues with larger side chains at the equivalent posi-
tions, maintaining the interaction with LEDGF (Figure 6).
The side chain of HIV-1 IN Trp-131 is involved in hydro-
phobic contacts with Phe-406 and Val-408 in LEDGF. The
bulky hydrophobic Trp residue, critical to the high-affinity
interaction (54), is substituted with small polar Asn in FIV
IN (Figure 6). The residues 167–171 comprising a connector
between a4 and a5 helices in HIV-1 IN CCD are directly
involved in the interaction with LEDGF. The hydrogen
bond between the side chains of Gln-168 and Trp-132 in
HIV-1 IN is thought to stabilize the conformation of the
connector. Although, the interaction is highly sensitive to
mutations at the positions 132 and 168 in HIV-1 IN
Figure 5. Sequence analysis of cloned EIAV and BIV integration products. (A) Pie charts summarizing the categories of clones obtained by cloning of the gel-
purified concerted linear integration products. In total, 30 EIAV- and 26 BIV- derived clones were analyzed. See the Results section for more details. (B)
Distribution of the cloned concerted integration events along the pGEM target. The histogram bars represent numbers of EIAV (black) and BIV (gray) integration
events within each 25 bp window along the target DNA sequence. The ruler corresponds to nucleotide coordinates within pGEM-9Zf() (GenBank accession no.
X65312). Positions of the plasmid’s replication origin (ori) and the ampicillin resistance gene (bla) are indicated.
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(20,54), neither residue is conserved in non-primate lentiviral
INs (Figure 6). A structure of a non-primate lentiviral IN in
complex with LEDGF IBD would elucidate the adaptive
changes evolved to preserve the interaction. Maintenance of
the interaction despite the significant differences between
the INs at the sequence level, suggests that engaging
LEDGF provided a strong selective advantage and played a
vital role in the evolution of Lentivirus.
LEDGF robustly stimulated in vitro strand transfer activity
of the divergent HIV-1, BIV and EIAV INs. Importantly, in
the presence of the co-factor the strand transfer occurred at
the physiological salt concentration and did not require
molecular crowding agents or dimethyl sulfoxide typically
added to observe magnesium-dependent activity of retroviral
INs (55–59). Of note, the co-solvent can alleviate dependence
of other nucleotidyl transferases from protein co-factors. For
instance, Mu phage transposition critically depends on a
network of protein–protein and protein–DNA interactions
(62). However, all elements of its intricate regulatory circuit,
including the host cell factor HU, become dispensable in the
presence of dimethyl sulfoxide (63). Stimulation of the
divergent lentiviral INs strongly suggests that the host factor
is intimately involved in regulation of lentiviral DNA
integration.
Surprisingly, the fidelity of the LEDGF-dependent strand
transfer varied broadly: the host factor selectively stimulated
concerted integration activity of EIAV IN, triggered
almost exclusive half-site strand transfer by HIV-1 IN, and
unleashed both activities in the BIV enzyme. Presumably,
both viral cDNA termini in vivo and a pair of donor mole-
cules in vitro must be brought together prior to concerted
strand transfer. Protein–protein interactions involving IN sub-
units and possibly co-factors associated with the cDNA ends
would mediate such synapsis. The fact that the in vitro
LEDGF-dependent activities of HIV-1 and BIV INs fall
short of reproducing legitimate integration might indicate a
requirement for an additional host cell- or virus- derived
co-factor. Conceivably, the minimal in vitro requirements
for proper assembly of the lentiviral synaptic complex depend
on stability of individual interfaces between the elements of
the integration machinery. Thus, a tighter interaction between
substrate-bound EIAV IN protomers could make the hypo-
thetic co-factor dispensable for concerted integration in
vitro. Further analyses will be necessary to explain the differ-
ences between in vitro activities of the lentiviral IVs and the
mechanism of stimulation of lentiviral INs by the host factor.
Intriguingly, LEDGF can both enhance and ablate concerted
integration activity of HIV-1 IN in vitro, depending on the
solution conditions and IN/LEDGF input ratio (K. Pandey
and D. Grandgenett, personal communication). The available
data collectively suggest that LEDGF can be a key regulator
of lentiviral integration.
The current generations of retroviral vectors rely on the
wild type viral integration machinery that evolved for
maximal viral fitness. The safety of gene therapy could be
drastically improved if an option of directed integration
could be added to these vectors. The strong bias towards inte-
gration into transcription units appears to be a unique feature
of Lentivirus (8–17), mirroring the genus-specific interaction
with LEDGF. HIV-1 integration into transcription units was
diminished in cells partially depleted for LEDGF, indicating
that the host factor at least contributed to the integration
target site selection (40). Alongside with recent work from
several laboratories (42–45), the data presented here indicate
that LEDGF is hardwired into the mechanism of lentiviral
DNA integration. These developments provide a stronger
foundation for further research into exploitation of the host
factor for directed retroviral gene delivery and as a potential
target for antiretroviral therapy.
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Figure 6. Partial sequence alignment of lentiviral INs. Secondary structure elements from 2B4J (32) are indicated above the alignment. Residues comprising the
a4/5 connector (167–171 in HIV-1 IN) (32) are boxed. Residues invariant among all six proteins are white on red background, and those with conserved
biochemical properties are bold on yellow background. Blue circles and boxes under the alignment indicate residues that in HIV-1 CCD-IBD structure directly
participate in the interaction with LEDGF through side chain or backbone atoms, respectively (32). The numbering corresponds to the HIV-1 sequence. The
figure was generated using ESPript-2.2 (64), (http://espript.ibcp.fr).
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